Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Leukemia, acute myeloid (AML), adult
Stage/Subtype:  untreated adult acute myeloid leukemia
Trial Type:  Treatment
Results 1-25 of 103 for your search:
Start Over
Bortezomib and Sorafenib Tosylate in Treating Patients with Newly Diagnosed Acute Myeloid Leukemia
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: Under 30
Trial IDs: AAML1031, NCI-2011-02670, CDR0000701850, COG-AAML1031, NCT01371981
Tretinoin and Arsenic Trioxide in Treating Patients with Untreated Acute Promyelocytic Leukemia
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 12 to 21
Trial IDs: AAML1331, NCI-2014-02266, PAAML1331_A01PAMDREVW0, NCT02339740
Quizartinib With Standard of Care Chemotherapy and as Maintenance Therapy in Patients With Newly Diagnosed FLT3-ITD (+) AML
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 to 75
Trial IDs: AC220-A-U302, NCI-2016-00846, NCT02668653
Transplantation of Ex Vivo Expanded, UCB-derived, Stem & Progenitor Cells vs. Unmanipulated UCB for HM Patients
Status: Active
Phase: Phase III
Type: Treatment
Age: 16 to 60
Trial IDs: GC P#05.01.020, NCI-2016-01518, NCT02730299
Study of Iomab-B Prior to HCT vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory AML
Status: Active
Phase: Phase III
Type: Treatment
Age: 55 and over
Trial IDs: Iomab-01, NCI-2016-01853, NCT02665065
Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Status: Temporarily closed
Phase: Phase III
Type: Treatment
Age: 60 and over
Trial IDs: E2906, NCI-2011-01992, CDR0000659585, ECOG-E2906, NCT01041703, NCT02085408
A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Subjects With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: M15-656, NCI-2017-00774, 2016-001466-28, NCT02993523
An Efficacy and Safety Study Of Pracinostat In Combination With Azacitidine In Adults With Acute Myeloid Leukemia
Status: Not yet active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: PRAN-16-52, NCI-2017-01215, NCT03151408
Sorafenib, Vorinostat, and Bortezomib in Treating Patients With Acute Myeloid Leukemia
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: IUCRO-0327, NCI-2012-00200, NCT01534260
Laboratory-Treated T Cells in Treating Patients with High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated with Donor Stem Cell Transplant
Status: Temporarily closed
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: Not specified
Trial IDs: 2498.00, NCI-2011-03362, 2498, NCT01640301
Inotuzumab Ozogamicin, Fludarabine Phosphate, Bendamustine Hydrochloride, and Rituximab before Donor Stem Cell Transplant in Treating Patients with Lymphoid Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 70
Trial IDs: 2012-0265, NCI-2012-02072, NCT01664910
Azacitidine in Treating Patients Undergoing Matched Unrelated Stem Cell Transplant
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 65
Trial IDs: 201303012, NCI-2012-03105, NCT01747499
Safety and Efficacy Study of PD-616 Plus Cytarabine to Treat Acute Myelogenous Leukemia or Myelodysplastic Syndrome
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 75
Trial IDs: RT12-US-AML-a, NCI-2013-01362, NCT01795924
AC220 With 5-Aza or Low Dose Cytarabine
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: Not specified
Trial IDs: 2012-1047, NCI-2013-02274, P50CA100632, NCT01892371
Chemotherapy and Donor Lymphocytes in Treating Older Patients with High-Risk Acute Myeloid Leukemia or Myelodysplastic Syndrome
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: 55 and over
Trial IDs: Pro00043247, NCI-2014-00663, NCT02046122
Partially-Matched Donor Stem Cell Transplant in Treating Younger Patients with High-Risk Hematologic Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: Not specified
Trial IDs: SCT 0813, NCI-2015-00141, CMH 13H11, CMH SCT 0813, NCT02053545
Binimetinib in Treating Patients with Relapsed, Refractory, or Poor Prognosis Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Acute Lymphoblastic Leukemia
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2013-0116, NCI-2014-01518, NCT02089230
SL-401 in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: STML-401-0114, NCI-2014-01146, NCT02113982
An Investigational Immuno-therapy Study of Ulocuplumab in Combination With Low Dose Cytarabine in Patients With Newly Diagnosed Acute Myeloid Leukemia
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 65 and over
Trial IDs: CA212-016, NCI-2017-00423, NCT02305563
Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in AML
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GMI-1271-201, NCI-2015-01237, NCT02306291
Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML)
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: GS-US-339-1559, NCI-2016-00088, NCT02343939
A Study of E6201 for the Treatment of Advanced Hematologic Malignancies With FLT3 Mutation
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: BSC-101-01, NCI-2015-00719, NCT02418000
Idarubicin, Cytarabine, and Nivolumab in Treating Patients with High-Risk Acute Myeloid Leukemia or Myelodysplastic Syndrome
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2014-0907, NCI-2015-01258, NCT02464657
Start Over